NPT100-18A
NPT100-18A is an αSyn oligomerization inhibitor. NPT10018A rescues cleaved caspase-3 levels to control levels. NPT10018A attenuates mitochondrial oxidative stress probe levels in a compartment-specific manner and, at higher concentrations, increases ATP signals. NPT100-18A can be used for the study of Parkinson’s disease (PD).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C28H39N5O3
- Masse moléculaire:493.64
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform α-synuclein
MoreVoir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
Description
IC50 & Target
|
Caspase 3 |
In Vitro
NPT100-18A (10 nM) reduces the amount of Triton-X100 insoluble αSyn aggregated conformers in iPSC-derived mDANs[1].
NPT100-18A (10 nM) specifically reduces mitochondrial ROS in iPSC-derived mDANs without affecting total intracellular ROS[1].
NPT100-18A (1 µM) significantly increases ATP signaling in iPSC-derived mDANs[1].
NPT100-18A (10 nM, 21 days) significantly reduces the proportion of cCasp3⁺ neurons in iPSC-derived mDANs and inhibits the αSyn-related early neuronal apoptosis pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:mThy1-wt-α-syn transgenic mice[2].
-
Dosage:1 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg
-
Administration:I.p., once daily for 90 days
-
Result:10 and 20 mg/kg significantly reduced foot slips.
10 mg/kg significantly improved the error rate in the Challenger beam test.
Accumulation of α-synuclein in neurons and neurites was reduced.
SDS-resistant α-synuclein oligomers were reduced.
α-synuclein changed from a membrane component to a cytoplasmic component.
-
Animal Model:mThy1-E57K-α-syn transgenic mice[2].
-
Dosage:20 mg/kg
-
Administration:I.p., once daily for 90 days
-
Result:Significantly reduced α-syn dimer/trimer/polymers.
Oligomer accumulation decreased markedly.
Chemical Information
-
Masse moléculaire 493.64
-
Formule C28H39N5O3
-
SMILES
O=C1N(CC2CCNCC2)CC(N(C(CCC3=CNC4=C3C=CC=C4)=O)CCC5=O)N5C1CCCC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Alecu JE, et al. NPT100-18A rescues mitochondrial oxidative stress and neuronal degeneration in human iPSC-based Parkinson's model. BMC Neurosci. 2025 Jan 28;26(1):8. [Content Brief]
[2]. Wrasidlo W, et al. A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease. Brain. 2016 Dec;139(Pt 12):3217-3236. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NPT100-18A Related Classifications
HY-156898 Related Classifications
Powered by Bioz